“…Additionally, Ecadherin loss appears to result in activation of the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/Akt signaling pathway, irrespective of oncogenic mutations in PIK3CA [12]. Somatic mutations in ILC differ from those in IDC, with increased prevalence of mutations in FOXA1, AKT1, PTEN, HER2, HER3, and FGFR4 seen in HR-positive, HER2negative ILC compared to HR-positive, HER2-negative IDC [8,13,14]. Within ILC, specific gene expression signatures have recently been described, providing evidence for heterogeneity within this tumor type and potential predictors of response to therapy [7,15,16] Upon clinical presentation, patients with ILC face unique challenges starting with delays in diagnosis and imprecision of clinical staging.…”